S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.47%) $27.23
Platinum
(0.41%) $924.25
USD/EUR
(0.32%) $0.935
USD/NOK
(0.80%) $11.04
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.32%) $91.87

Realtime updates for Anavex Life Sciences Corp [AVXL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
75.00%
return 4.77%
SELL
75.00%
return 1.82%
Last Updated26 Apr 2024 @ 16:00

1.47% $ 3.44

SELL 105393 min ago

@ $5.61

Issued: 13 Feb 2024 @ 15:41


Return: -38.68%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: -3.28 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):
Profile picture for Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases...

Stats
Today's Volume 949 959
Average Volume 1.32M
Market Cap 278.08M
EPS $0 ( 2024-02-05 )
Next earnings date ( $-0.110 ) 2024-05-07
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.37
ATR14 $0.00600 (0.17%)
Insider Trading
Date Person Action Amount type
2024-03-28 Missling Christopher U Buy 73 380 Common Stock
2024-03-28 Missling Christopher U Sell 73 380 Common Stock
2024-03-28 Missling Christopher U Sell 73 380 Stock Option (Right to Buy)
2024-02-20 Donhauser Peter D.o. Buy 50 000 Stock Option (Right to Buy)
2024-02-20 Thomas Steffen Buy 50 000 Stock Option (Right to Buy)
INSIDER POWER
3.52
Last 100 transactions
Buy: 6 187 971 | Sell: 2 192 392

Volume Correlation

Long: -0.21 (neutral)
Short: -0.01 (neutral)
Signal:(52.383) Neutral

Anavex Life Sciences Corp Correlation

10 Most Positive Correlations
BLCM0.903
VISL0.903
ALLO0.899
GURE0.891
CPIX0.89
RLMD0.883
CADL0.877
CMLF0.875
ALGS0.874
ENTA0.874
10 Most Negative Correlations
XOG-0.919
BNIXU-0.893
FIZZ-0.892
IMRX-0.872
PT-0.86
EPZM-0.857
ANSS-0.846
WLTW-0.839
SGEN-0.838
AMRB-0.831

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anavex Life Sciences Corp Correlation - Currency/Commodity

The country flag 0.24
( neutral )
The country flag 0.29
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.15
( neutral )

Anavex Life Sciences Corp Financials

Annual 2023
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.600
FY 2023
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.600
FY 2022
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.620
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-0.540

Financial Reports:

No articles found.

Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators